New Drug Shows Promising Results in Phase 3 Trial

In a significant advancement for Parkinson's disease (PD) treatment, NeuroDerm Ltd., a subsidiary of Mitsubishi Tanabe Pharma Corporation, announced the results of the Phase 3 BouNDless trial published in The Lancet Neurology. The study found that ND0612, a continuous subcutaneous infusion of levodopa/carbidopa (LD/CD), was superior to oral immediate-release LD/CD in managing motor fluctuations in PD patients. Parkinson's disease affects over 10 million people globally and is characterized by the death of dopamine-producing cells in the brain, leading to motor symptoms that impact daily living. Levodopa, combined with carbidopa, is a cornerstone of PD treatment. However, oral levodopa's effectiveness can decrease over time, causing motor fluctuations. The BouNDless trial showed that ND0612 significantly increased "ON" time (periods without troublesome dyskinesia) by 1.72 hours and reduced "OFF" time (periods when medication effects wear off) by 1.4 hours compared to oral LD/CD. These results suggest a potential paradigm shift in PD management, particularly for patients experiencing motor fluctuations with current oral therapies. The study also highlighted improvements in patients' quality of life, as measured by the Movement Disorders Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II scores and global impressions of change from both patients and clinicians. ND0612's safety profile was consistent with oral LD/CD, with infusion site reactions being the most reported adverse events. Notably, dyskinesia, falls, and ON/OFF phenomena were less frequent in the ND0612 group. With these promising results, ND0612 could become a new, less invasive treatment option for PD patients. The medical community awaits the U.S. Food and Drug Administration's decision, expected in the second quarter of 2024, which could usher in a new era in PD treatment focused on continuous innovation and patient-centered care.